Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Clinical cancer research

Results: 26-50/3141

Authors: Tanaka-Nozaki, M Onda, M Tanaka, N Kato, S
Citation: M. Tanaka-nozaki et al., Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels, CLIN CANC R, 7(9), 2001, pp. 2783-2787

Authors: Calogero, A Arcella, A De Gregorio, G Porcellini, A Mercola, D Liu, CT Lombari, V Zani, M Giannini, G Gagliardi, FM Caruso, R Gulino, A Frati, L Ragona, G
Citation: A. Calogero et al., The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas, CLIN CANC R, 7(9), 2001, pp. 2788-2796

Authors: Dalbagni, G Ren, ZP Herr, H Cordon-Cardo, C Reuter, V
Citation: G. Dalbagni et al., Genetic alterations in TP53 in recurrent urothelial cancer: A longitudinalstudy, CLIN CANC R, 7(9), 2001, pp. 2797-2801

Authors: Coomber, DWJ Ward, RL
Citation: Dwj. Coomber et Rl. Ward, Isolation of human antibodies against the central DNA binding domain of p53 from an individual with colorectal cancer using antibody phage display, CLIN CANC R, 7(9), 2001, pp. 2802-2808

Authors: Kamijo, T Yokose, T Hasebe, T Yonou, H Hayashi, R Ebihara, S Ochiai, A
Citation: T. Kamijo et al., Image analysis of microvessel surface area predicts radiosensitivity in early-stage laryngeal carcinoma treated with radiotherapy, CLIN CANC R, 7(9), 2001, pp. 2809-2814

Authors: Kataoka, A Sadanaga, N Mimori, K Ueo, H Barnard, GF Sugimachi, K Auclair, D Chen, LB Mori, M
Citation: A. Kataoka et al., Overexpression of HRad17 mRNA in human breast cancer: Correlation with lymph node metastasis, CLIN CANC R, 7(9), 2001, pp. 2815-2820

Authors: Silva, JM Dominguez, G Silva, J Garcia, JM Sanchez, A Rodriguez, O Provencio, M Espana, P Bonilla, F
Citation: Jm. Silva et al., Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics, CLIN CANC R, 7(9), 2001, pp. 2821-2825

Authors: Kodama, J Hashimoto, I Seki, N Hongo, A Yoshinouchi, M Okuda, H Kudo, T
Citation: J. Kodama et al., Thrombospondin-1 and-2 messenger RNA expression in invasive cervical cancer: Correlation with angiogenesis and prognosis, CLIN CANC R, 7(9), 2001, pp. 2826-2831

Authors: Raida, M Schwabe, W Hausler, P Van Kuilenburg, ABP Van Gennip, AH Behnke, D Hoffken, K
Citation: M. Raida et al., Prevalence of a common point mutation in the Dihydropyrimidine dehydrogenase (DPD) gene within the 5 '-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls, CLIN CANC R, 7(9), 2001, pp. 2832-2839

Authors: Slaton, JW Karashima, T Perrotte, P Inoue, K Kim, SJ Izawa, J Kedar, D McConkey, DJ Millikan, R Sweeney, P Yoshikawa, C Shuin, T Dinney, CPN
Citation: Jw. Slaton et al., Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cellcarcinoma of the bladder, CLIN CANC R, 7(9), 2001, pp. 2840-2853

Authors: Szepeshazi, K Schally, AV Halmos, G Sun, BD Hebert, F Csernus, B Nagy, A
Citation: K. Szepeshazi et al., Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptorsubtypes 5 and/or 3 in experimental pancreatic cancers, CLIN CANC R, 7(9), 2001, pp. 2854-2861

Authors: Holden, SA Lan, Y Pardo, AM Wesolowski, JS Gillies, SD
Citation: Sa. Holden et al., Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents, CLIN CANC R, 7(9), 2001, pp. 2862-2869

Authors: Davidoff, AM Ng, CYC Brown, P Leary, MA Spurbeck, WW Zhou, JF Horwitz, E Vanin, EF Nienhuis, AW
Citation: Am. Davidoff et al., Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice, CLIN CANC R, 7(9), 2001, pp. 2870-2879

Authors: Lin, VCL Eng, AS Hen, NE Ng, EHL Chowdhury, SH
Citation: Vcl. Lin et al., Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231, CLIN CANC R, 7(9), 2001, pp. 2880-2886

Authors: Nishizaki, M Meyn, RE Levy, LB Atkinson, EN White, RA Roth, JA Ji, L
Citation: M. Nishizaki et al., Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo, CLIN CANC R, 7(9), 2001, pp. 2887-2897

Authors: Weinstein-Oppenheimer, CR Henriquez-Roldan, CF Davis, JM Navolanic, PM Saleh, OA Steelman, LS Franklin, RA Robinson, PJ McMahon, M McCubrey, JA
Citation: Cr. Weinstein-oppenheimer et al., Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin, CLIN CANC R, 7(9), 2001, pp. 2898-2907

Authors: Li, WW Takahashi, N Jhanwar, S Cordon-Cardo, C Elisseyeff, Y Jimeno, J Faircloth, G Bertino, JR
Citation: Ww. Li et al., Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: Identification of ecteinascidin-743 as a potent cytotoxic agent, CLIN CANC R, 7(9), 2001, pp. 2908-2911

Authors: Nicoletti, MI Valoti, G Giannakakou, P Zhan, ZR Kim, JH Lucchini, V Landoni, F Mayo, JG Giavazzi, R Fojo, T
Citation: Mi. Nicoletti et al., Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-anticancer drug screen: Correlation with sensitivity to microtubule active agents, CLIN CANC R, 7(9), 2001, pp. 2912-2922

Authors: Aherne, GW Hardcastle, A Ward, E Dobinson, D Crompton, T Valenti, M Brunton, L Jackman, AL
Citation: Gw. Aherne et al., Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules, CLIN CANC R, 7(9), 2001, pp. 2923-2930

Authors: Rowland-Goldsmith, MA Maruyama, H Kusama, T Ralli, S Korc, M
Citation: Ma. Rowland-goldsmith et al., Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation, CLIN CANC R, 7(9), 2001, pp. 2931-2940

Authors: Hobisch, A Ramoner, R Fuchs, D Godoy-Tundidor, S Bartsch, G Klocker, H Culig, Z
Citation: A. Hobisch et al., Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype, CLIN CANC R, 7(9), 2001, pp. 2941-2948

Authors: Sausville, EA
Citation: Ea. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequenceand tumor biology matters - Commentary re: P. Munster et al., modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001., CLIN CANC R, 7(8), 2001, pp. 2155-2158

Authors: Zhang, W Laborde, PM Coombes, KR Berry, DA Hamilton, SR
Citation: W. Zhang et al., Cancer genomics: Promises and complexities, CLIN CANC R, 7(8), 2001, pp. 2159-2167

Authors: Shah, MA Schwartz, GK
Citation: Ma. Shah et Gk. Schwartz, Cell cycle-mediated drug resistance: An emerging concept in cancer therapy, CLIN CANC R, 7(8), 2001, pp. 2168-2181

Authors: Mathijssen, RHJ van Alphen, RJ Verweij, J Loos, WJ Nooter, K Stoter, G Sparreboom, A
Citation: Rhj. Mathijssen et al., Clinical pharmacokinetics and metabolism of irinotecan (CPT-11), CLIN CANC R, 7(8), 2001, pp. 2182-2194
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>